Improving bioavailability using predictive modeling for solubility enhancement
Low solubility can limit systemic exposure, increasing the risk of unpredictable outcomes and creating a barrier to clinical progression. In this case study, predictive modeling with the OSDPredict™ platform was used to prioritize optimal formulation strategies for a program facing low-solubility challenges. This approach improved exposure and supported accelerated advancement toward Phase I clinical trials.
Using the OSDPredict™ platform, scientists were able to:
- Assess solubility limitations and their impact on bioavailability
- Predict in vivo exposure across different formulation approaches
- Prioritize optimal formulation strategies earlier in development
- Enable more informed decision-making before clinical studies
Key outcomes of an optimized HPMCAS-M formulation
- Improved systemic exposure for a poorly soluble compound
- Accelerated progression toward Phase I clinical studies
- Reduced formulation risk through data-driven strategy selection
- Increased confidence in candidate viability for clinical trials
Access the case study: https://www.patheon.com/us/en/insights-resources/case-studies/improving-bioavailability-with-predictive-modeling.html
Total Page Views: 32
